(-0.01%) 5 477.75 points
(-0.02%) 38 810 points
(0.01%) 19 924 points
(0.26%) $80.54
(1.11%) $2.82
(0.10%) $2 331.40
(-0.43%) $29.27
(-0.13%) $969.60
(0.03%) $0.932
(-0.12%) $10.64
(0.08%) $0.788
(-1.86%) $86.81
Live Chart Being Loaded With Signals
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform...
Stats | |
---|---|
Šios dienos apimtis | 486 396 |
Vidutinė apimtis | 609 358 |
Rinkos kapitalizacija | 733.54M |
EPS | $-0.240 ( Q1 | 2024-05-10 ) |
Kita pelno data | ( $-0.160 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-11.75 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00900 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | Moran Kyle | Sell | 15 630 | Ordinary Shares |
2024-02-05 | Francis Chris | Buy | 286 400 | Share Option (right to buy) |
2024-02-05 | Bolno Paul | Buy | 1 008 600 | Share Option (right to buy) |
2024-02-05 | Moran Kyle | Buy | 371 500 | Share Option (right to buy) |
2024-02-05 | Vargeese Chandra | Buy | 361 700 | Share Option (right to buy) |
INSIDER POWER |
---|
98.39 |
Last 99 transactions |
Buy: 37 730 786 | Sell: 301 457 |
Tūris Koreliacija
WAVE Life Sciences Ltd Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
HALO | 0.841 |
MNKD | 0.835 |
CARA | 0.823 |
ICLR | 0.816 |
STRL | 0.816 |
ESGR | 0.814 |
OKTA | 0.804 |
ORGS | 0.804 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
NERV | -0.811 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
WAVE Life Sciences Ltd Koreliacija - Valiuta/Žaliavos
WAVE Life Sciences Ltd Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $113.31M |
Bruto pelnas: | $104.10M (91.88 %) |
EPS: | $-0.540 |
FY | 2023 |
Pajamos: | $113.31M |
Bruto pelnas: | $104.10M (91.88 %) |
EPS: | $-0.540 |
FY | 2022 |
Pajamos: | $3.65M |
Bruto pelnas: | $-6.47M (-177.17 %) |
EPS: | $-2.05 |
FY | 2021 |
Pajamos: | $40.96M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-2.36 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
WAVE Life Sciences Ltd
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.